Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome

Histopathology

Volumn 69, Issue 1, 2016, Pages 25-34

  Beckers, Rhiannon K ^a   Selinger, Christina I ^a   Vilain, Ricardo ^a,b,c   Madore, Jason ^c   Wilmott, James S ^b,c   Harvey, Kate ^a,d   Holliday, Anne ^d   Cooper, Caroline L ^a,b   Robbins, Elizabeth ^a   Gillett, David ^b,e   Kennedy, Catherine W ^b,e   Gluch, Laurence ^b,e,f   Carmalt, Hugh ^a,b,e   Mak, Cindy ^a   Warrier, Sanjay ^a,b,g   Gee, Harriet E ^a,h   Chan, Charles ^b,f   McLean, Anna ^b   Walker, Emily ^b   McNeil, Catriona M ^b,i   Beith, Jane M ^b,i   Swarbrick, Alexander ^d,j   Scolyer, Richard A ^a,b,c   O'Toole, Sandra A ^a,b,d,j   more..

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MELANOMA INSTITUTE AUSTRALIA   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e Strathfield Breast Centre   (Australia)

^f Department of Microbiology and Infectious Diseases   (Australia)

^g PRINCE OF WALES HOSPITAL   (Australia)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ Chris O'Brien Lifehouse ^*  (Australia)

^j UNIVERSITY OF NEW SOUTH WALES   (Australia)

more..

Author keywords

PDL1; triple negative breast cancer; tumour infiltrating lymphocytes

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL MEMBRANE; CLINICAL FEATURE; COHORT ANALYSIS; DISTANT METASTASIS; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; VERY ELDERLY;

EID: 84974717586     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12904     Document Type: Article

References (33)

1. Australian Institute of Health and Welfare (AIHW). Breast Cancer in Australia: An Overview. Cancer series no. 71. Cat. no. CAN 67. Canberra: AIHW, 2012.
2. Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J. 2010; 16; 53–61.
3. Keir ME, Liang SC, Guleria I et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 2006; 203; 883–895.
4. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 2012; 24; 207–212.
5. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol. Immunother. 2005; 54; 307–314.
6. Taube JM, Klein AP, Brahmer JR et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 2014; 20; 5064–5074.
7. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-l1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012; 366; 2455–2465.
8. Nanda R, Chow LQ, Dees EC. Abstract s1-09: a phase IB study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. 2014 San Antonio Breast Cancer Symposium (SABCS). San Antonio, Texas, 2014.
9. Emens LA, Braiteh FS, Cassier P. Abstract PD1-6: inhibition of PD-L1 by mpdl3280a leads to clinical activity in patients with metastatic triple-negative breast cancer. 2014 San Antonio Breast Cancer Symposium (SABCS). San Antonio, Texas, 2014.
10. Muenst S, Schaerli AR, Gao F et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res. Treat. 2014; 146; 15–24.
11. Schalper KA, Velcheti V, Carvajal D et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin. Cancer Res. 2014; 20; 2773–2782.
12. Mittendorf EA, Philips AV, Meric-Bernstam F et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol. Res. 2014; 2; 361–370.
13. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19; 403–410.
14. Cheang MCU, Voduc D, Bajdik C et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 2008; 14; 1368–1376.
15. Gadiot J, Hooijkaas AI, Kaiser AD, van Tinteren H, van Boven H, Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 2011; 117; 2192–2201.
16. Hino R, Kabashima K, Kato Y et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010; 116; 1757–1766.
17. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin. Cancer Res. 2004; 10; 5094–5100.
18. Adams S, Gray RJ, Demaria S et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J. Clin. Oncol. 2014; 32; 2959–2967.
19. Loi S. Host antitumor immunity plays a role in the survival of patients with newly diagnosed triple-negative breast cancer. J. Clin. Oncol. 2014; 32; 2935–2937.
20. Gatalica Z, Snyder C, Maney T et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol. Biomark. Prev. 2014; 23; 2965–2970.
21. Ghebeh H, Mohammed S, Al-Omair A et al. The b7-h1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006; 8; 190–198.
22. Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS ONE 2014; 9; e88557.
23. Rimm D, Schalper K, Pusztai L. Unvalidated antibodies and misleading results. Breast Cancer Res. Treat. 2014; 147; 457–458.
24. Muenst S, Tzankov A, Gillanders WE, Soysal SD. Author's response to ‘Letter to the editor: unvalidated antibodies and misleading results’. Breast Cancer Res. Treat. 2014; 147; 459–462.
25. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N. Engl. J. Med. 2012; 366; 2443–2454.
26. Loi S, Sirtaine N, Piette F et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: Big 02-98. J. Clin. Oncol. 2013; 31; 860–867.
27. Velcheti V, Schalper KA, Carvajal DE et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab. Invest. 2014; 94; 107–116.
28. Taube JM, Anders RA, Young GD et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 2012; 4; 127ra137.
29. Droeser RA, Hirt C, Viehl CT et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur. J. Cancer 2013; 49; 2233–2242.
30. Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515; 568–571.
31. Wimberly H, Brown JR, Schalper KA et al. PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol. Res. 2014; 3; 326–332.
32. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med. Oncol. 2011; 28; 682–688.
33. Thompson RH, Gillett MD, Cheville JC et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl Acad. Sci. USA 2004; 101; 17174–17179.